Bristol Myers Squibb announces ZENBEXUSTM combo results in myeloma

Bristol Myers Squibb said its ZENBEXUSTM (iberdomide) combination with daratumumab and dexamethasone showed superior progression-free survival versus standard of care in the Phase 3 EXCALIBER-RRMM study for relapsed/refractory multiple myeloma.